

Alessandra Aiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8465084/publications.pdf>

Version: 2024-02-01

17
papers

550
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

796
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. <i>Neurology</i> , 2022, 98, .	1.1	125
2	Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 740249.	4.8	70
3	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. <i>Microorganisms</i> , 2021, 9, 1315.	3.6	54
4	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 106, 338-347.	3.3	43
5	Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 846753.	4.8	37
6	An emerging interplay between extracellular vesicles and cytokines. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 49-60.	7.2	35
7	The Role of Extracellular Vesicles as Allies of HIV, HCV and SARS Viruses. <i>Viruses</i> , 2020, 12, 571.	3.3	35
8	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. <i>Scientific Reports</i> , 2022, 12, 6687.	3.3	31
9	Humoral and cellular responses to spike of $\hat{\nu}$ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. <i>International Journal of Infectious Diseases</i> , 2022, 121, 24-30.	3.3	21
10	Multi-omics approach to COVID-19: a domain-based literature review. <i>Journal of Translational Medicine</i> , 2021, 19, 501.	4.4	18
11	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	18
12	Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. <i>Vaccines</i> , 2021, 9, 615.	4.4	15
13	The involvement of plasmacytoid cells in HIV infection and pathogenesis. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 77-89.	7.2	14
14	Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	12
15	PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. <i>Frontiers in Immunology</i> , 2021, 12, 594376.	4.8	11
16	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. <i>Cells</i> , 2022, 11, 52.	4.1	11
17	HIV-1 Nef Protein Affects Cytokine and Extracellular Vesicles Production in the GEN2.2 Plasmacytoid Dendritic Cell Line. <i>Viruses</i> , 2022, 14, 74.	3.3	0